UY34959A - Dihidropiridona p1 as inhibitors of factor xia - Google Patents

Dihidropiridona p1 as inhibitors of factor xia

Info

Publication number
UY34959A
UY34959A UY0001034959A UY34959A UY34959A UY 34959 A UY34959 A UY 34959A UY 0001034959 A UY0001034959 A UY 0001034959A UY 34959 A UY34959 A UY 34959A UY 34959 A UY34959 A UY 34959A
Authority
UY
Uruguay
Prior art keywords
inhibitors
factor xia
dihidropiridona
p1
compounds
Prior art date
Application number
UY0001034959A
Other languages
Spanish (es)
Inventor
Yang Wu
James R Corte
Paul J Gilligan
Donald J P Pinto
William R Ewing
Wang Yufeng
Original Assignee
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201261679197P priority Critical
Priority to US201361786992P priority
Application filed by Bristol Myers Squibb Company Una Corporación Del Estado De Delaware filed Critical Bristol Myers Squibb Company Una Corporación Del Estado De Delaware
Publication of UY34959A publication Critical patent/UY34959A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18Bridged systems

Abstract

La presente invención provee compuestos de la Fórmula (VIII), o estereoisómeros, tautómeros o sales de aquellos aceptables desde el punto de vista farmacéutico, en donde todas las variables son como se definen en la presente. The present invention provides compounds of Formula (VIII), or stereoisomers, tautomers or salts of those acceptable from the pharmaceutical point of view, where all variables are as defined herein. Estos compuestos son inhibidores selectivos del factor XIa o inhibidores duales de FXIa y calicreína plasmática. These compounds are selective inhibitors of factor XIa inhibitors or dual plasma kallikrein and FXIa. La presente invención también se refiere a composiciones farmacéuticas que comprenden estos compuestos ya métodos para tratar trastornos tromboembólicos y/o inflamatorios mediante su uso. The present invention also relates to pharmaceutical compositions comprising these compounds and methods for treating thromboembolic disorders and / or inflammatory through use.
UY0001034959A 2012-08-03 2013-08-02 Dihidropiridona p1 as inhibitors of factor xia UY34959A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201261679197P true 2012-08-03 2012-08-03
US201361786992P true 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
UY34959A true UY34959A (en) 2014-01-31

Family

ID=48949289

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034959A UY34959A (en) 2012-08-03 2013-08-02 Dihidropiridona p1 as inhibitors of factor xia

Country Status (26)

Country Link
US (2) US9376444B2 (en)
EP (1) EP2882734B1 (en)
JP (1) JP6082462B2 (en)
KR (1) KR20150038369A (en)
AR (1) AR093759A1 (en)
AU (1) AU2013296258A1 (en)
BR (1) BR112015002293A2 (en)
CA (1) CA2880898A1 (en)
CY (1) CY1118450T1 (en)
DK (1) DK2882734T3 (en)
EA (1) EA025392B1 (en)
ES (1) ES2605824T3 (en)
HR (1) HRP20161378T1 (en)
HU (1) HUE031582T2 (en)
IL (1) IL237012D0 (en)
LT (1) LT2882734T (en)
MX (1) MX361370B (en)
PL (1) PL2882734T3 (en)
PT (1) PT2882734T (en)
RS (1) RS55581B1 (en)
SG (1) SG11201500270RA (en)
SI (1) SI2882734T1 (en)
SM (1) SMT201700003B (en)
TW (1) TW201410666A (en)
UY (1) UY34959A (en)
WO (1) WO2014022766A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201319068A (en) 2011-08-05 2013-05-16 Squibb Bristol Myers Co Cyclic P1 linkers as factor XIa inhibitors
TW201311689A (en) 2011-08-05 2013-03-16 Squibb Bristol Myers Co Novel macrocycles as factor XIa inhibitors
EP2899183B1 (en) 2011-10-14 2018-09-19 Bristol-Myers Squibb Company Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors
WO2013056034A1 (en) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
AU2012322085B2 (en) 2011-10-14 2017-05-04 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor Xia inhibitors
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
ES2668318T3 (en) 2012-10-12 2018-05-17 Bristol-Myers Squibb Company Crystal forms of factor XIa inhibitor
US9315519B2 (en) 2012-10-12 2016-04-19 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
US9738655B2 (en) 2013-03-25 2017-08-22 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors
TWI633089B (en) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 Substituted oxopyridine derivatives
AU2015210904C1 (en) * 2014-01-31 2019-08-29 Bristol-Myers Squibb Company Macrocycles with hetrocyclic P2' groups as factor XIa inhibitors
NO2760821T3 (en) 2014-01-31 2018-03-10
WO2015123093A1 (en) * 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Factor xia inhibitors
US9663527B2 (en) 2014-02-11 2017-05-30 Merck Sharp & Dohme Corp. Factor XIa inhibitors
US10081623B2 (en) 2014-09-04 2018-09-25 Bristol-Myers Squibb Company Diamide macrocycles that are FXIa inhibitors
NO2721243T3 (en) 2014-10-01 2018-10-20
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
US10160750B2 (en) 2015-06-19 2018-12-25 Bristol-Myers Squibb Company Diamide macrocycles as factor XIa inhibitors
CN107849026A (en) 2015-07-29 2018-03-27 百时美施贵宝公司 Carry alkyl or cycloalkyl P2,Partial factor XI, plasma thromboplastin antecedent A macrocyclic hcv inhibitors
KR20180073602A (en) * 2015-10-29 2018-07-02 머크 샤프 앤드 돔 코포레이션 Factor XIa inhibitor
EP3371162A4 (en) * 2015-10-29 2019-04-24 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use
EP3423458A1 (en) * 2016-03-02 2019-01-09 Bristol-Myers Squibb Company Diamide macrocycles having factor xia inhibiting activity
US10143681B2 (en) 2016-08-22 2018-12-04 Merck Sharp & Dohme Corp. Factor XIa inhibitors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3065190D1 (en) 1979-11-05 1983-11-10 Beecham Group Plc Enzyme derivatives, and their preparation
PE121699A1 (en) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Disubstituted bicyclic heterocycles as inhibitors of thrombin
ZA9805247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
AU5413600A (en) 1999-06-14 2001-01-02 Eli Lilly And Company Compounds
DE19962924A1 (en) 1999-12-24 2001-07-05 Bayer Ag Substituted oxazolidinones and their use
AR035216A1 (en) 2000-12-01 2004-05-05 Astrazeneca Ab Mandelic acid derivatives, pharmaceutically acceptable derivatives, use of these derivatives for the manufacture of medicaments, methods of treatment, processes for preparing these derivatives, and intermediate compounds
DE60233335D1 (en) 2001-09-21 2009-09-24 Bristol Myers Squibb Co Lactomatic compounds and their derivatives as factor xa hemmer
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
US7138412B2 (en) 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
EP1841504B1 (en) 2005-01-13 2014-11-19 Bristol-Myers Squibb Company Substituted biaryl compounds as factor xia inhibitors
US20060183771A1 (en) 2005-02-17 2006-08-17 Seiffert Dietmar A Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors
CN101341124A (en) 2005-12-14 2009-01-07 布里斯托尔-迈尔斯斯奎布公司 Six-membered heterocycles useful as serine protease inhibitors
WO2007070816A2 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Thiophene derivatives as factor xia inhibitors
AU2006325754B2 (en) 2005-12-14 2012-04-12 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors
CN101605779B (en) 2006-12-15 2013-11-20 百时美施贵宝公司 Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
PE20081775A1 (en) * 2006-12-20 2008-12-18 Squibb Bristol Myers Co Macrocyclic compounds as inhibitors of factor VIIa
CN101784516B (en) 2007-06-13 2014-07-02 百时美施贵宝公司 Dipeptide analogs as coagulation factor inhibitors
EP2265601B1 (en) 2008-03-13 2012-02-01 Bristol-Myers Squibb Company Pyridazine derivatives as factor xia inhibitors
TWI520965B (en) * 2010-02-11 2016-02-11 Squibb Bristol Myers Co As a class of macrocyclic inhibitors of factor xia
TW201311689A (en) 2011-08-05 2013-03-16 Squibb Bristol Myers Co Novel macrocycles as factor XIa inhibitors
TW201319068A (en) * 2011-08-05 2013-05-16 Squibb Bristol Myers Co Cyclic P1 linkers as factor XIa inhibitors
WO2013056034A1 (en) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2899183B1 (en) 2011-10-14 2018-09-19 Bristol-Myers Squibb Company Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors
AU2012322085B2 (en) 2011-10-14 2017-05-04 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor Xia inhibitors
NO2794597T3 (en) 2011-12-21 2018-04-14
JP2015083542A (en) 2012-02-08 2015-04-30 大日本住友製薬株式会社 Three substituted proline derivative
GB201209138D0 (en) 2012-05-24 2012-07-04 Ono Pharmaceutical Co Compounds

Also Published As

Publication number Publication date
EA025392B1 (en) 2016-12-30
EP2882734B1 (en) 2016-10-12
AR093759A1 (en) 2015-06-24
JP2015524443A (en) 2015-08-24
HUE031582T2 (en) 2017-07-28
PT2882734T (en) 2016-12-09
SI2882734T1 (en) 2017-01-31
IL237012D0 (en) 2015-03-31
US20140038969A1 (en) 2014-02-06
LT2882734T (en) 2016-12-12
MX2015000919A (en) 2015-09-21
EA201590284A1 (en) 2015-05-29
BR112015002293A2 (en) 2017-07-04
CY1118450T1 (en) 2017-06-28
SMT201700003B (en) 2017-03-08
SG11201500270RA (en) 2015-03-30
HRP20161378T1 (en) 2016-12-02
DK2882734T3 (en) 2017-01-30
PL2882734T3 (en) 2017-05-31
ES2605824T3 (en) 2017-03-16
KR20150038369A (en) 2015-04-08
RS55581B1 (en) 2017-06-30
US9376444B2 (en) 2016-06-28
TW201410666A (en) 2014-03-16
US20150166550A1 (en) 2015-06-18
CA2880898A1 (en) 2014-02-06
WO2014022766A1 (en) 2014-02-06
MX361370B (en) 2018-12-05
EP2882734A1 (en) 2015-06-17
AU2013296258A1 (en) 2015-03-19
CN104520289A (en) 2015-04-15
JP6082462B2 (en) 2017-02-15

Similar Documents

Publication Publication Date Title
CL2018000150A1 (en) Compounds useful as immunomodulators (divisional application 201600508)
CL2014001793A1 (en) Compounds derived from 1,3,5-triazines and their salts, as inhibitors of IDH2 mutant; pharmaceutical composition which comprises; and its use for the treatment of cancer.
AR091837A1 (en) Compounds for targeted immunotherapy
CR20150487A (en) Biaryl compounds as kinase inhibitors amide
CU20100219A7 (en) And quinoxaline quinoline derivatives as inhibitors of protein tyrosine kinase
ECSP11011306A (en) Benzofuranyl derivatives
MY162936A (en) Macrocycles as factor xia inhibitors
UY35590A (en) Novel compounds for treating cancer
CU20130101A7 (en) Derivatives of 1,4-oxazin-3-yl-pyridin-2-yl-acetamide, active as inhibitors BACE or BACE-1-2
UY35242A (en) Inhibitors phosphatidylinositol 3-kinase
DOP2015000158A (en) PRMT5 inhibitors and their uses
PE20150669A1 (en) Benzamide derivatives for the inhibition of the activity of ABL1, ABL2 and bcr-ABL1
TR201905814T4 (en) bipyrazol salt as a JAK inhibitor.
GT201400133A (en) Bromodominios inhibitors
UY35257A (en) Picolinamides macrocyclic as fungicides, compositions and methods for controlling plant diseases
UY35617A (en) Inhibitors of phosphatidylinositol 3-kinase
CY1119281T1 (en) Kainofaneis macrocycles as a operator XIA INHIBITORS
CU24039B1 (en) Halogenated imidazolidin-2-one 1,3-disubstituted as CYP17 inhibitors
BR112014008807A2 (en) substituted tetrahydroisoquinoline compounds as factor xia inhibitors
CL2016002027A1 (en) Cyclopropylamine as LSD1 inhibitor
CO6710897A2 (en) Poperdinona derivatives as inhibitors for the treatment of mdm2 cancer
UY34550A (en) substituted Bencilpirazoles
UY34051A (en) Pirrolotriazinona derivatives as inhibitors of PI3K
PE20151788A1 (en) Tetracyclic inhibitors bromodominios
CR20130410A (en) Compounds and compositions as inhibitors of trk